|
|
The Hong Kong-based venture is developing an asset-light, technology-driven approach to private blood banking, supported by patent-pending intellectual property, specialist clinical expertise and early interest from prospective clients.
HONG KONG – November 18, 2026 – MiCells Limited (MiCells®), a Hong Kong-based healthcare technology startup developing private autologous blood banking solutions, has been selected for pre-incubation and acceleration support through an initiative involving China Resources Group and Hong Kong Science and Technology Parks Corporation (HKSTP).
The selection marks another milestone for the early-stage venture as it advances plans to establish a new category of private biological preparedness for high-net-worth and ultra-high-net-worth individuals.
The China Resources-HKSTP collaboration aims to support emerging technology companies through industry engagement, entrepreneurship development and opportunities for expansion into mainland China. For MiCells, participation presents an opportunity to develop strategic relationships and explore the Greater Bay Area as part of its longer-term international growth strategy.
A Business Born from Personal Experience
The inspiration for MiCells originated from founder and CEO Ben Cooper’s personal experience following a serious rugby injury in Hong Kong in 2014.
Requiring major surgery, his O-negative blood type presented an unexpected challenge. There was insufficient compatible blood available locally, resulting in a 48-hour operative delay while additional supplies were flown in from overseas.
O-negative blood is particularly scarce in Hong Kong, accounting for approximately 0.4% of the blood-group distribution recorded in Hong Kong Red Cross Blood Transfusion Service’s 2023 donation data, compared with around 8% of the population in the West.
Nearly a decade later, the decision to preserve his newborn son’s cord blood through long-term cryogenic storage prompted a broader question about personal biological preparedness.
“If we can preserve our children’s cord blood for the future, why isn’t long-term preservation of our own blood more readily accessible?” “That question ultimately became MiCells,” says Cooper.

The concept raises a further question about patient choice. During planned surgical procedures, including hip and knee replacements, clinicians assess and manage the risk of blood loss and potential transfusion requirements. While preoperative autologous blood donation is not routinely recommended for most procedures, having access to previously stored personal blood could offer an additional option in selected clinical circumstances.
Speaking about the company’s origins and ambitions, Cooper commented:
“Having personally experienced the challenges of blood availability, I began questioning why individuals couldn’t take greater control of their own biological preparedness. Donated blood saves lives every day, but we believe patients should have more options where clinically appropriate and financially viable.
Hong Kong is a natural place to build this business. With its exceptional life expectancy, growing interest in longevity, concentration of high-net-worth individuals and strategic access to the Greater Bay Area, we believe it offers an ideal launchpad for international expansion.
Our selection for the China Resources-HKSTP programme is an encouraging milestone as we work towards establishing an entirely new category of private biological preparedness.”
Co-founded alongside Chief Technology Officer Clint Pavlovic, MiCells is developing a service designed to enable individuals to privately preserve their own blood for potential future medical requirements, supported by specialist clinical infrastructure and international logistics.
The company’s clinical development is supported by Chief Medical Officer Dr Anil Bhalla, a twenty year specialist in blood transfusion medicine, who contributes clinical expertise to the development of MiCells’ service model and its engagement with healthcare providers.
Unlike conventional blood banking models primarily serving healthcare institutions, MiCells aims to introduce a premium, individually managed approach to biological preparedness, combining long-term cryogenic preservation with secure specimen identification, authenticated chain of custody and controlled clinical release, subject to clinical suitability and applicable regulatory requirements.
Technology-Led, Asset-Light Expansion
Central to the company’s strategy is an asset-light operating model, designed to leverage established clinical, laboratory, cryogenic storage and specialist logistics providers rather than requiring extensive proprietary physical infrastructure.
The approach is intended to support capital-efficient international expansion while maintaining a high-value service model built around initial onboarding, recurring annual fees and specialist deployment services.
MiCells has also filed a Hong Kong patent application covering technology for persistent biological specimen identity, privacy-preserving verification and authenticated chain-of-custody management across independent healthcare environments.
The technology is intended to provide a secure foundation for managing biological assets throughout their operational lifecycle, from collection and processing to long-term storage, transportation and authorised clinical release.
Early Market Interest and Institutional Recognition
MiCells has received 26 non-binding expressions of interest from prospective clients, providing an encouraging early indication of market demand ahead of commercial launch.
The company is targeting an initial 45 onboarded clients by the second quarter of 2028, reflecting a business model focused on high-value client relationships rather than mass-market volumes.
The China Resources-HKSTP selection follows MiCells’ acceptance into HKSTP’s Ideation ecosystem, further strengthening its connections within Hong Kong’s innovation and technology community.
With Hong Kong serving as its initial market, MiCells intends to explore opportunities across the Greater Bay Area and subsequently other international markets through a partner-led expansion strategy.
Building a New Category of Private Healthcare Infrastructure
Combining proprietary technology, specialist clinical expertise, premium service economics and an asset-light operating model, MiCells is positioning itself at the intersection of healthcare infrastructure, biological asset management and international logistics.
Its longer-term ambition is to establish a trusted international network for private biological preparedness, offering eligible individuals greater personal choice, traceability and coordination in managing their own biological resources.
About MiCells
MiCells Limited is a Hong Kong-based healthcare technology venture developing private autologous blood banking and biological preparedness solutions for high-net-worth individuals and families.
Website         LinkedIn        X/Twitter
For strategic partnerships, investment opportunities or commercial enquiries, please contact: [email protected]

Tell Us What You Think!